Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

S. Poli-Bigelli, José Rodrigues-Pereira, Alexandra D. Carides et al. · Cancer · 2003 · 566 citations

Medicine, Oncology, Pharmacology +17

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

Richard J. Gralla, M. Lichinitser, S. van der Vegt et al. · Annals of Oncology · 2003 · 471 citations

Medicine, Oncology, Pharmacology +17

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

Mitsue Saito, Kenjiro Aogi, Ikuo Sekine et al. · The Lancet Oncology · 2009 · 434 citations

Medicine, Oncology, Pharmacology +14

Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis

Michel Marty, P Pouillart, Jean Pierre Droz et al. · New England Journal of Medicine · 1990 · 411 citations

Medicine, Pharmacology, Pharmacotherapy +17

Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT₃ receptor antagonist

Peter D. Eisenberg, Jazmin Figueroa‐Vadillo, Rosalio Zamora et al. · Cancer · 2003 · 404 citations · Full text

Medicine, Oncology, Pharmacology +17